Pending regulatory approvals, the UBC-Tilray study is poised to be one of the first in the world to run a large-scale clinical trial examining medical cannabis as a treatment for a mental health disorder.
FOUR20 owns and operates six stores in Alberta and has secured 16 additional high-traffic store locations
Agreement is for up to C$110M subject to the achievement of performance milestones by FOUR20
NYU School of Medicine will lead trials testing CBD treatment for patients with Alcohol Use Disorder and Post-Traumatic Stress Disorder with Alcohol Use Disorder
Additional 20 hectares of outdoor growing space increases company’s capacity to supply medical cannabis across Europe and to other international markets
Ireland becomes the 13th country with Tilray medical cannabis products as company continues global expansion in Europe and increases access to patients in need